ArticleBone marrow transplantation2016
The patient's CMV serological status affects clinical outcome after T-cell replete haplo-HSCT and post-transplant cyclophosphamide.
R Crocchiolo et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
17 papers cite it
this papercites it